A Phase IIa Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of HP515 Tablets in Participants With Non - Alcoholic Fatty Liver Disease
Latest Information Update: 02 Jan 2026
At a glance
- Drugs HP 515 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Hinova pharmaceuticals
Most Recent Events
- 02 Jan 2026 New trial record